![Lysosomal Acid Lipase Deficiency / Wolman disease / Cholesteryl ester storage disease / Lysosomal storage disease / Mucopolysaccharidosis / Rare diseases / Lipid storage disorders / Health Lysosomal Acid Lipase Deficiency / Wolman disease / Cholesteryl ester storage disease / Lysosomal storage disease / Mucopolysaccharidosis / Rare diseases / Lipid storage disorders / Health](https://www.pdfsearch.io/img/48377d9ebd9bea6e3a29b8ade4327978.jpg)
| Document Date: 2014-03-03 16:19:48 Open Document File Size: 432,79 KBShare Result on Facebook
City RESULTS LEXINGTON / / Company Synageva BioPharma Corp. / / Country United States / / Currency USD / / Event Conference Call / FDA Phase / Earnings Announcement / Earnings Guidance / / IndustryTerm manufacturing facility / biopharmaceutical company developing therapeutic products / drug product / developed technology / manufacturing platform / manufacturing capabilities / / MedicalCondition mucopolysaccharidosis IIIB / accelerated atherosclerosis / LAL Deficiency LAL Deficiency / rare diseases / storage disease / disease / cirrhosis / lysosomal acid lipase deficiency / Cholesteryl Ester Storage Disease / MPS IIIB The mucopolysaccharidoses / Wolman disease / rare disorders / diseases / deficiency / LAL Deficiency / B syndrome / / MedicalTreatment enzyme replacement therapy / biologic therapies / / Organization European Medicines Agency / U.S. Food and Drug Administration / FDA / Ministry of Health / / Person MPS IIIB / / / Position general business update / animal model / / Product Fuzeon / SBC-103 / / ProvinceOrState Massachusetts / / Technology alpha / / URL www.synageva.com / /
SocialTag |